KOREA PHARMA (032300) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, KOREA PHARMA (032300) reported revenue of 87.6 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
202587.6 billion KRW-887 million KRW-2.6 billion KRW[source]
202481.3 billion KRW6.1 billion KRW3.8 billion KRW[source]
202383.2 billion KRW6.3 billion KRW84 million KRW[source]
202281.0 billion KRW6.2 billion KRW-1.1 billion KRW[source]
202179.6 billion KRW5.0 billion KRW6.4 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025126.6 billion KRW57.9 billion KRW68.8 billion KRW[source]
2024112.4 billion KRW40.9 billion KRW71.4 billion KRW[source]
2023121.3 billion KRW52.7 billion KRW68.6 billion KRW[source]
2022130.9 billion KRW71.1 billion KRW59.8 billion KRW[source]
2021129.4 billion KRW71.9 billion KRW57.5 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice